A regulatory role for the C5a anaphylatoxin in, type 2 immunity in asthma

2006 | journal article. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​A regulatory role for the C5a anaphylatoxin in, type 2 immunity in asthma​
Kohl, J.; Baelder, R.; Lewkowich, I. P.; Pandey, M. K.; Hawlisch, H.; Wang, L. H. & Best, J. et al.​ (2006) 
Journal of Clinical Investigation116(3) pp. 783​-796​.​ DOI: https://doi.org/10.1172/JCI26582 

Documents & Media

License

GRO License GRO License

Details

Authors
Kohl, J.; Baelder, R.; Lewkowich, I. P.; Pandey, Manoj K.; Hawlisch, H.; Wang, L. H.; Best, J.; Herman, N. S.; Sproles, A. A.; Zwirner, Joerg; Whitsett, J. A.; Gerard, Jean-Pierre; Sfyroera, G.; Lambris, John D.; Wills-Karp, M.
Abstract
Complement component 5 (CS) has been described as either promoting or protecting against airway hyper-responsiveness (AHR):in experimental allergic asthma, suggesting pleomorphic effects of C5. Here we report that local pharmacological targeting of the C5a receptor (C5aR) prior to initial allergen sensitization in murine models of inhalation tolerance or allergic asthma resulted in either induction or marked enhancement of Th2-polarized immune responses, airway inflammation, and AHR. Importantly, C5aR-deficient mice exhibited a similar, increased allergic phenotype. Pulmonary allergen exposure in CSaR-targeted mice resulted in increased sensitization and accumulation of CD4(+)CD69(+) T cells associated with a marked increase in pulmonary myeloid, but not plasmacytoid, DC numbers. Pulmonary DCs from C5aR-targeted mice produced large amounts of CC chemokine ligand 17 (CCL17) and CCL22 ex vivo, suggesting a negative impact of C5aR signaling on pulmonary homing of Th2 cells. In contrast, C5aR targeting in sensitized mice led to suppressed airway inflammation and AHR but was still associated with enhanced production of Th2 effector cytokines. These data suggest a dual role for C5a in allergic asthma, i.e., protection from the development of maladaptive type 2 immune responses during allergen sensitization at the DC/T cell interface but enhancement of airway inflammation and AHR in an established inflammatory environment.
Issue Date
2006
Status
published
Publisher
Amer Soc Clinical Investigation Inc
Journal
Journal of Clinical Investigation 
ISSN
0021-9738

Reference

Citations


Social Media